AUTL News and Press, Autolus Therapeutics plc From 03/05/21

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2020 Q4 earnings call. For further details see: Autolus Therapeutics plc 2020 Q4 - Results - Earnings Call Presentation

Autolus Therapeutics plc (AUTL) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Lucinda Crabtree – Vice President-Investor Relations Christian Itin – Chairman and Chief Executive Officer Andrew Oakley – Chief Financial Officer Conference Cal...

Autolus Therapeutics (AUTL): FY GAAP EPS of -$2.76 misses by $0.10.Revenue of $1.72M beats by $0.2M.Shares -1% PM.Press Release For further details see: Autolus Therapeutics EPS misses by $0.10, beats on revenue

LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended Decemb...

LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. ...

Autolus shares have been in decline since September last year as the CAR-T therapy developer has raised further funding and its trials have been disrupted by the pandemic. Nevertheless, lead candidate AUTO-1 has entered a >100 patient pivotal trial in ALL and data suggests this cou...

Autolus Therapeutics (AUTL) announced the closing of its previously announced underwritten public offering of 16.4M American Depositary Shares ((ADSs)), with gross proceeds of about $115M.The company also said that the underwriters used their option in full to purchase an additional...

LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten public offering in the United States of ...

Comstock Holding Companies (CHCI) -15%.VerifyMe (VRME) -15% on stock offering.Neovasc (NVCN) -14% on stock offering; pared yesterday's gains on patent news.Enlivex Therapeutics (ENLV) -13% on stock offering.Salem Media Group (SALM) -13%.Limbach Holdings (LMB) ...

Autolus Therapeutics (AUTL) has priced its public offering of ~14.3M ADSs at $7.00/ADS, for total gross proceeds of ~$100M. Each ADS representing one ordinary share.Underwriters' over-allotment is an additional ~2.1M ADSs.Closing date is February 12.Shares down 1.3% premarket.P...